Agile Sciences, Inc. is an emerging biopharmaceutical company that is pioneering an entirely new mechanistic approach for the treatment of antibiotic resistant, life-threatening infections.
Agile Sciences’ core technology consists of a new class of 2-aminoimidazole (2-AI) small molecules that inhibit bacterial resistance mechanisms through a novel mode of action resulting in enhanced antibiotic activity.
Agile Sciences is exploiting the above attributes of the 2-AI compounds in three therapeutic areas that are difficult-to-treat:
1) Multidrug-resistant bacterial infections
2) Lung infections in cystic fibrosis patients
3) Chronic wound infections